Literature DB >> 3193498

Use of a caval-atrial shunt for resection of a caval tumor thrombus in renal cell carcinoma.

R S Foster1, Y Mahomed, R Bihrle, S Strup.   

Abstract

Extraction of a tumor thrombus in the vena cava from a renal cell carcinoma is a technically demanding but gratifying procedure. We describe a technique for isolation of the superior vena cava during thrombus extraction using an inferior vena caval to atrial shunt.

Entities:  

Mesh：

Year:  1988        PMID： 3193498     DOI： 10.1016/s0022-5347(17)42047-7

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


  4 in total

1.  Experience with cardiopulmonary bypass and deep hypothermic circulatory arrest in the management of retroperitoneal tumors with large vena caval thrombi.

Authors:  A C Novick; M C Kaye; D M Cosgrove; K Angermeier; J E Pontes; J E Montie; S B Streem; E Klein; R Stewart; M Goormastic
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

2.  Benefits of liver transplantation surgical techniques in the management of extensive retroperitoneal tumors.

Authors:  Marcelo E Facciuto; Manoj K Singh; Juan P Rocca; Caroline Rochon; Manuel I Rodriguez Davalos; Majid Eshghi; David M Schwalb; Muhammad Choudhury; Patricia A Sheiner
Journal:  World J Surg       Date:  2008-11       Impact factor: 3.352

3.  Treatment of renal cell carcinoma with a level III or level IV inferior vena cava thrombus using cardiopulmonary bypass and deep hypothermic circulatory arrest.

Authors:  Yong-Hui Chen; Xiao-Rong Wu; Zhen-Lei Hu; Wei-Jun Wang; Chen Jiang; Wen Kong; Wei Chen; Wei Xue; Dong-Ming Liu; Yi-Ran Huang
Journal:  World J Surg Oncol       Date:  2015-04-22       Impact factor: 2.754

4.  The role of deep hypothermic circulatory arrest in surgery for renal or adrenal tumor with vena cava thrombus: a single-institution experience.

Authors:  Peng Zhu; Songlin Du; Shijun Chen; Shaobin Zheng; Yu Hu; Li Liu; Shaoyi Zheng
Journal:  J Cardiothorac Surg       Date:  2018-07-05       Impact factor: 1.637
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.